124 results
6-K
EX-99.3
AMYT
Amryt Pharma Plc
11 May 22
Current report (foreign)
4:30pm
EXHIBIT 99.3
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label … of the study as responders - insulin-like growth factor 1 (IGF-1) within normal limits - maintained their long-term biochemical response at the end
6-K
EX-99.3
AMYT
Amryt Pharma Plc
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety and efficacy profile of Mycapssa® … support the long-term safety and efficacy of Mycapssa® in acromegaly patients who were previously biochemically controlled on monthly injectable
424B3
AMYT
Amryt Pharma Plc
31 Jan 22
Prospectus supplement
7:35am
control. For additional information, please follow this link.
Mycapssa® (oral octreotide) is approved in the US for long-term maintenance therapy … approval of Mycapssa® for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide
424B3
AMYT
Amryt Pharma Plc
31 Jan 22
Prospectus supplement
7:33am
control. For additional information, please follow this link.
Mycapssa® (oral octreotide) is approved in the US for long-term maintenance therapy … approval of Mycapssa® for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide
6-K
EX-99.4
AMYT
Amryt Pharma Plc
31 Jan 22
Current report (foreign)
7:32am
EXHIBIT 99.4
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management … that was statistically significant.
- The study demonstrated that patients maintained their long-term biochemical response with 94%, 90% and 93% of patients
6-K
EX-99.2
c691d042p4spupy x3m
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
424B3
ktvwwm
31 Mar 22
Prospectus supplement
8:44am
6-K
EX-99.2
afb6z2h6
31 Mar 22
Results of General Meeting
8:41am
424B3
s2izfokmilk
4 May 22
Prospectus supplement
8:35am
6-K
EX-99.1
cr8ee ic317z
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
424B3
h6fap8lsfsbgd
4 Mar 21
Prospectus supplement
8:38am
424B3
8opx44f kzs
31 Mar 22
Prospectus supplement
8:44am
6-K
EX-99.2
17z6q44rdcik6kexk5j
11 May 22
Current report (foreign)
4:30pm
6-K
EX-99.5
osr31z 24
4 Aug 22
Results of Annual General Meeting
7:38am
424B3
ennl4m7q1q4 rptqr4
2 Jun 21
Prospectus supplement
10:08am
6-K
EX-99.3
un449211ry08co
4 Aug 22
Results of Annual General Meeting
7:38am
6-K
EX-99.3
gowmxezjkaybo9hpym0c
31 Mar 22
Results of General Meeting
8:41am
6-K
EX-99.5
xfrkft1ornfdbj
5 May 21
Agreement and Plan of Merger
5:19pm
6-K
EX-99.1
v00b55i
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
EX-99.2
6ypv3n0f5jvh
31 Jan 22
Current report (foreign)
7:32am